The following criteria is provided for health care professionals.

Key Phase 1 Inclusion Criteria

1. ECOG Performance Status of 0-1
2. Measurable disease
3. Willing to undergo a tumor biopsy
4. Histologically-proven B cell malignancies, meeting the following criteria:
   1. Relapsed, refractory B-cell non-Hodgkin lymphoma requiring therapy
   2. Relapsed, refractory chronic lymphocytic leukemia requiring therapy
   3. Relapsed or progressive multiple myeloma on or after treatment
5. Histologically-proven solid tumor meeting the following criteria:
   1. Metastatic breast cancer
   2. Recurrent squamous cell carcinoma of the head and neck
   3. Ovarian cancer
   4. Soft tissue sarcoma
   5. Recurrent metastatic or locally advanced pancreatic cancer

Key Phase 2 Inclusion Criteria

1. ECOG Performance Status of 0-1
2. Measurable disease defined by disease-specific response criteria
3. Site of disease amenable to a biopsy and willing to undergo a biopsy
4. Biomarker positive on recent biopsy or bone marrow sample
5. Histologically-proven B cell malignancies, meeting the following criteria: DLBCL, MCL, or Multiple Myeloma requiring therapy
6. Histologically-proven solid tumors: Triple Negative Breast Cancer, Ovarian Cancer or biomarker positive cancers

Key Exclusion Criteria

1. Known history of brain metastases, unless treated (Phase 1 only) .
2. Known history of meningeal involvement or meningeal carcinomatosis
3. Spinal cord compression not definitively treated with surgery and/or radiation
4. Laboratory assessments
   1. ANC < 1.0 x 10^9/L; PLT < 75 x 10^9/L; Hgb < 9.0 g/dL
   2. Calculated Creatinine clearance (Cockcroft-Gault) < 60 mL/min
   3. Hepatic function: AST > 2.0 x ULN; ALT > 2.0 x ULN; Total bilirubin > 1.5 ; Albumin < 2.8 g/dL
5. Screening QTc interval > 450 milliseconds (males) and > 470 ms for females